TMO supply chain intelligence for Thermo Fisher Scientific Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Thermo Fisher Scientific Inc. (TMO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CLARIO-HOLDINGS-INC | CLARIO-HOLDINGS-INC | 92% | With the transaction complete, the Clario business will become part of Thermo Fisher’s Laboratory Products and Biopharma Services segment. |
| BTAI | BioXcel Therapeutics, Inc. | 85% | Reciprocal relationship from BTAI graph: Reciprocal relationship from TMO graph: Reciprocal relationship from BTAI graph: lization of our products or to produce our products in accordance with cGMP p… |
| ICLR | ICON Public Limited Company | 85% | Reciprocal relationship from ICLR graph: Reciprocal relationship from TMO graph: Reciprocal relationship from ICLR graph: responsibility for the maintenance of key client relationships. Our aim is to… |
| IMTX | Immatics N.V. | 85% | Reciprocal relationship from IMTX graph: A”) with Patheon UK Limited (“Patheon”), a subsidiary of Thermo Fisher Scientific Inc., for certain manufacturing and quality control services. The Agreement … |
| IONS | Ionis Pharmaceuticals, Inc. | 85% | Reciprocal relationship from IONS graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IONS graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IONS gra… |
| AZTA | Azenta, Inc. | 72% | Reciprocal relationship from AZTA graph: que portfolio of products and services. Each segment, however, has unique competitors in their area of offerings. In the Sample Management Solutions segment, … |
| BHP | BHP Group Limited | 72% | Reciprocal relationship from BHP graph: 127 Table of Contents Catherine Tanna Bachelor of Laws, Honorary Doctor of Business Appointment Independent Non-executive Director since April 2022 Skills and … |
| CLLS | Cellectis S.A. | 72% | Reciprocal relationship from CLLS graph: ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, … |
| DNA | Ginkgo Bioworks Holdings, Inc. | 72% | Reciprocal relationship from DNA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from DNA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from DNA graph:… |
| GH | Guardant Health, Inc. | 72% | Reciprocal relationship from GH graph: r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests. In addition, we ar… |
| HRMY | Harmony Biosciences Holdings, Inc. | 72% | Reciprocal relationship from HRMY graph: Reciprocal relationship from TMO graph: Reciprocal relationship from HRMY graph: (“API”). ● Corden Pharma Chenôve SAS, a full-service contract development and… |
| IDXG | Interpace Biosciences, Inc. | 72% | Reciprocal relationship from IDXG graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IDXG graph: tests from sole suppliers. We also purchase components used in our collection… |
| IDXX | IDEXX Laboratories, Inc. | 72% | Reciprocal relationship from IDXX graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IDXX graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IDXX gra… |
| IQV | IQVIA Holdings Inc. | 72% | Reciprocal relationship from IQV graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IQV graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IQV graph:… |
| MEDP | Medpace Holdings, Inc. | 72% | Reciprocal relationship from MEDP graph: d and disciplined approach facilitates strong account evaluation, which results in increased focus by the sales team, the management of sales force effectiven… |
| MXCT | MaxCyte, Inc. | 72% | Reciprocal relationship from MXCT graph: Reciprocal relationship from TMO graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from TMO graph: Reciprocal relationship from MXCT gra… |
| PACB | Pacific Biosciences of California, Inc. | 72% | Reciprocal relationship from PACB graph: Reciprocal relationship from TMO graph: Reciprocal relationship from PACB graph: We manufacture sequencing instruments, SMRT Cells, and reagents. Our key manu… |
| RGEN | Repligen Corporation | 72% | Reciprocal relationship from RGEN graph: uct categories as well as several large companies, including Danaher Corporation (Cytiva), Thermo Fisher Scientific Inc., MilliporeSigma and Sartorius. Many o… |
| SOLV | Solventum Corporation | 72% | Reciprocal relationship from SOLV graph: Reciprocal relationship from TMO graph: Reciprocal relationship from SOLV graph: Reciprocal relationship from TMO graph: Reciprocal relationship from SOLV gra… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: Reciprocal relationship from TMO graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from TMO graph: Reciprocal relationship from SUPN gra… |
| TWST | Twist Bioscience Corporation | 72% | Reciprocal relationship from TWST graph: ies, Inc., Eurofins Genomics Blue Heron, Elegen Corporation, Ansa Biotechnologies, Inc., Telesis Bio, Inc. and others. Additionally, we compete with both larg… |
| VCYT | Veracyte, Inc. | 72% | Reciprocal relationship from VCYT graph: Reciprocal relationship from TMO graph: Reciprocal relationship from VCYT graph: y requirements, which may be subject to change, and our failure to comply wit… |
| WAT | Waters Corporation | 72% | Reciprocal relationship from WAT graph: Reciprocal relationship from TMO graph: Reciprocal relationship from WAT graph: Reciprocal relationship from TMO graph: Reciprocal relationship from WAT graph:… |
| BGMS | Bio Green Med Solution, Inc. | 62% | Reciprocal relationship from BGMS graph: ket risks could have a detrimental effect on the availability of sources of funding and our ability to access them in the future. Until we can generate a suff… |
| CLWT | Euro Tech Holdings Company Limited | 62% | Reciprocal relationship from CLWT graph: . The Company distributes supplies manufactured by a number of vendors. Thermo Fisher Scientific Group (“Thermo”), Stanford Research Systems, Inc. (“Stanford”… |
| NSPR | InspireMD, Inc. | 62% | Reciprocal relationship from NSPR graph: to educate an adequate number of physicians of the benefits of CGuard Prime over alternative treatment options; and 38 ● unforeseen costs and expenses associa… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CLARIO-HOLDINGS-INC | CLARIO-HOLDINGS-INC | 92% | With the transaction complete, the Clario business will become part of Thermo Fisher’s Laboratory Products and Biopharma Services segment. |
| HUMA | Humacyte, Inc. | 90% | Reciprocal relationship from HUMA graph: We source bioprocess solutions, including culture media and decellularization buffers, from a division of Thermo Fisher Scientific |
| PCVX | Vaxcyte, Inc. | 90% | Reciprocal relationship from PCVX graph: In September 2025, we also entered into a master services agreement with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific (collectively, “… |
| TECH | Bio-Techne Corporation | 90% | Reciprocal relationship from TECH graph: Reciprocal relationship from TMO graph: Reciprocal relationship from TECH graph: we sell through a distribution agreement with Thermo Fisher Scientific |
| AZTA | Azenta, Inc. | 72% | Reciprocal relationship from AZTA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from AZTA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from AZTA gra… |
| DEO | Diageo plc | 72% | the responsible use of emerging technologies such as generative artificial intelligence (AI). These include comprehensive frameworks such as the EU’s General Data Protection Regulation (GDPR), the EU… |
| DEO | Diageo plc | 72% | Reciprocal relationship from DEO graph: Reciprocal relationship from TMO graph: Reciprocal relationship from DEO graph: Reciprocal relationship from TMO graph: the responsible use of emerging technol… |
| GH | Guardant Health, Inc. | 72% | Reciprocal relationship from GH graph: r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests. In addition, we ar… |
| HRMY | Harmony Biosciences Holdings, Inc. | 72% | Reciprocal relationship from HRMY graph: (“API”). ● Corden Pharma Chenôve SAS, a full-service contract development and manufacturing organization (“CDMO”) manufactures our API. ● Procos, S.p.A. opera… |
| IDXG | Interpace Biosciences, Inc. | 72% | Reciprocal relationship from IDXG graph: tests from sole suppliers. We also purchase components used in our collection kits from sole-source suppliers. Some of these items are unique to these supplie… |
| IMTX | Immatics N.V. | 72% | Reciprocal relationship from IMTX graph: A”) with Patheon UK Limited (“Patheon”), a subsidiary of Thermo Fisher Scientific Inc., for certain manufacturing and quality control services. The Agreement … |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: vestigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue … |
| MEDP | Medpace Holdings, Inc. | 72% | Reciprocal relationship from MEDP graph: d and disciplined approach facilitates strong account evaluation, which results in increased focus by the sales team, the management of sales force effectiven… |
| MXCT | MaxCyte, Inc. | 72% | Reciprocal relationship from MXCT graph: doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adop… |
| PACB | Pacific Biosciences of California, Inc. | 72% | Reciprocal relationship from PACB graph: We manufacture sequencing instruments, SMRT Cells, and reagents. Our key manufacturing and service facility in Menlo Park, California has received ISO 13485 a… |
| RGEN | Repligen Corporation | 72% | Reciprocal relationship from RGEN graph: uct categories as well as several large companies, including Danaher Corporation (Cytiva), Thermo Fisher Scientific Inc., MilliporeSigma and Sartorius. Many o… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: Reciprocal relationship from TMO graph: Reciprocal relationship from SUPN graph: Reciprocal relationship from TMO graph: Reciprocal relationship from SUPN gra… |
| SVRA | Savara Inc. | 72% | Reciprocal relationship from SVRA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from SVRA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from SVRA gra… |
| TWST | Twist Bioscience Corporation | 72% | Reciprocal relationship from TWST graph: ies, Inc., Eurofins Genomics Blue Heron, Elegen Corporation, Ansa Biotechnologies, Inc., Telesis Bio, Inc. and others. Additionally, we compete with both larg… |
| VCYT | Veracyte, Inc. | 72% | Reciprocal relationship from VCYT graph: y requirements, which may be subject to change, and our failure to comply with these requirements could substantially harm our business. Certain of our produc… |
| WAT | Waters Corporation | 72% | Reciprocal relationship from WAT graph: rs continuously introduce new products and have instrument businesses that are generally more diversified than the Company’s business. Some competitors have gr… |
| ABOUT-THERMO-FISHER-SCIENTIFIC-THERMO-FISHER-SCI | ABOUT-THERMO-FISHER-SCIENTIFIC-THERMO-FISHER-SCI | 62% | . As previously announced, the acquisition is expected to contribute $0.45 of adjusted earnings per share (EPS) 1 in the first year after close. Details on the positive impact on Thermo Fisher’s 2026… |
| NORDIC-CAPITAL-NOVO-HOLDINGS | NORDIC-CAPITAL-NOVO-HOLDINGS | 62% | . As previously announced, the acquisition is expected to contribute $0.45 of adjusted earnings per share (EPS) 1 in the first year after close. Details on the positive impact on Thermo Fisher’s 2026… |
| OPERATIONS-THERMO-FISHER-SCIENTIFIC-INC | OPERATIONS-THERMO-FISHER-SCIENTIFIC-INC | 62% | 442 $ 17,286 $ 47,364 56 $ ( 15,133 ) $ ( 3,224 ) $ 46,735 $ ( 11 ) $ 46,724 Issuance of shares under stock plans — 2 2 376 — — ( 67 ) — 310 — 310 Stock-based compensation — — — 301 — — — — 301 — 301… |
| OVERVIEW-THERMO-FISHER-SCIENTIFIC-INC | OVERVIEW-THERMO-FISHER-SCIENTIFIC-INC | 62% | ommission (SEC). Forward-looking statements in this Management’s Discussion and Analysis of Financial Condition and Results of Operations speak only as of the dates on which they are made. While the … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| TMO-DEBT | Debt stack $22.1B | 90% | Market cache reports total debt of $22.1B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| TMO-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 2594 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BIO | Bio-Rad Laboratories, Inc. | 100.00 | 2 | |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 2 | |
| ACET | Adicet Bio, Inc. | 100.00 | 2 | |
| BHPLF | BHP Group Limited | 100.00 | 1 | ['spend'] |
| BMY | Bristol-Myers Squibb Company | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | ['customer'] |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| RGEN | Repligen Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 100.00 | 2 | |
| DGX | Quest Diagnostics Incorporated | 100.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 100.00 | 2 | |
| CLWT | Euro Tech Holdings Company Limited | 100.00 | 1 | ['supplier'] |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| GRAL | GRAIL, Inc. | 100.00 | 2 | |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| SUPN | Supernus Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| IMO | Imperial Oil Limited | 100.00 | 2 | |
| GDTC | CytoMed Therapeutics Limited | 100.00 | 2 |